The new tale of some old drugs



In-silico drug repositioning is a recent trend in drug discovery that aims at revealing new pharmacological properties for drugs that are already in medical practice. We present the results of a new approach in drug repositioning, which employs clustering and community detection in drug-drug interaction networks. As such, we built a drug-drug interaction complex network (i.e., interactome), where nodes represent drugs and links represent the interactions between drugs according to DrugBank4.1. By applying a combination of two clustering methods, namely energy model layout and modularity algorithms, we generated 9 topological communities and 7 modularity classes respectively. The pharmacological properties for 85% of the analyzed drugs are confirmed by other drug databases, and specialized literature. However, 15% of the drugs do not exhibit the pharmacological properties indicated by their topological communities or modularity classes; therefore, these properties are considered repositioning hints. Some of these hints were tested by in vivo and in vitro experiments, as well as by clinical trials. Here, we present such examples of drug repositioning hints that were subsequently investigated and confirmed.


Table of Contents:

1. Introduction

2. Methodology

3. Results

4. Conclusion


To read the contribution click here.


The Authors:

UDRESCU Lucreția [1]

SBÂRCEA Laura [1]

[1] Faculty of Pharmacy,Victor Babeș” University of Medicine and Pharmacy Timișoara (ROMANIA).


Contributo selezionato da Filodiritto tra quelli pubblicati nei Proceedings “17th Romanian National Congress oh Pharmacy – 21st Century Pharmacy – Between Intelligent Specialization and Social Responsibility - 2018”

Per acquistare i Proceedings clicca qui.


Contribution selected by Filodiritto among those published in the Proceedings “17th Romanian National Congress oh Pharmacy – 21st Century Pharmacy – Between Intelligent Specialization and Social Responsibility - 2018”

To buy the Proceedings click here.


1.    Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8, p. 959.

2.    Pammolli, F., et al., (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery 10, pp. 428.

3.    Graul, A., et al., (2014). The years new drugs & biologics, 2013: Part I. Drugs Today (Barc) 50, p. 51.

4.    Wishart, D.S, et al., (2006). Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research 34, p. D668.

5.    Udrescu, L., et al., (2016). Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing. Scientific Reports 6:32745.

6.    Mihăicuță, Ș., et al., (2017). Network science meets respiratory medicine for OSAS phenotyping and severity prediction. PeerJ 5: e3289.

7.    Jacomy, M., et al., (2014). Forceatlas2, a continuous graph layout algorithm for handy network visualization designed for the gephi software. PloS One 9(6): e98679

8.    Topirceanu, A., et al., (2018). Weighted betweenness preferential attachment: a new mechanism explaining social network formation and evolution. Scientific Reports 8: 10871

9.    Topirceanu, A., Udrescu, M. (2017). Statistical fidelity: a tool to quantify the similarity between multi-variable entities with application in complex networks. International Journal of Computer Mathematics 94(9), p. 1787.

10. Gupta, A., et al., (2016). Fusidic acid inhibits hepatic transporters and metabolic enzymes: potential cause of clinical drug-drug interaction observed with statin coadministration. Antimicrobial Agents and Chemotherapy 60(10), p. 5986.

1.    11.Yao, J., et al., (2013). Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate. Journal of Controlled Release 170(3), p. 414.

11. Shafique, S., Rashid, S. (2017). Antiviral drug acyclovir exhibits antitumor activity via targeting βTrCP1: Molecular docking and dynamics simulation study. Journal of Molecular Graphics and Modelling 72, p. 96.

12. Falciani, M., et al., (2001). Effects of nebivolol on human platelet aggregation. Journal of Cardiovascular Pharmacology 38(6), p. 922.

13. Grill, M.F., Maganti, R.K. (2011). Neurotoxic effects associated with antibiotic use: management considerations. British Journal of Clinical Pharmacology 72(3), p. 381.

14., available at, last time accesed in august 2018

15. Uivarosi, V. (2013). Metal Complexes of Quinolone Antibiotics and Their Applications: An Update. Molecules 18, p. 11153.

16. Dobrek, Ł., et al., (2016). The influence of montelukast on the activity of the autonomic nervous system estimated by heart rate variability in experimental partial bladder outlet obstruction in rats. Acta Poloniae Pharmaceutica 73(3), p. 777.

17. Jain, S., Besag, F.M. (2013). Does melatonin affect epileptic seizures? Drug Safety 36(4), p. 207.

18. Rocha, A.K.A.A. (2017) Altered MT1 and MT2 melatonin receptors expression in the hippocampus of pilocarpine-induced epileptic rats. Epilepsy & Behavior 71, p. 23.

19. A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer. Identifier: NCT03144804. Available at